Health Workers Lead the Charge, Receiving First COVID-19 Vaccines in Rochester, New York
At Strong Memorial Hospital, employees received the COVID-19 vaccine and spoke about why they believe it is important to get vaccinated.
Neuriva®: Clinically proven plant-sourced ingredients to support brain health
Complete the form below to download this White Paper from Neuriva®.
Following the release of the Biden administration’s COVID-19 response strategy, NCPA issued its support and urged the government to also consider engaging independent pharmacies in its implementation.
Amantadine, a treatment that was originally used as an agent against influenza A, lost efficacy due to viral resistance.
Pharmacy Times® interviewed Brian Nightengale, president of Good Neighbor Pharmacy, on how the recent unanimous SCOTUS ruling on Rutledge v. PCMA will impact independent pharmacies across the country.
The approach is being developed specifically as a potential treatment for the significant fraction of people with debilitating depression who do not respond to existing therapies and are at high risk of suicide.
Study finds that death was significantly less likely for type 2 diabetes subjects taking metformin, compared to those not taking metformin.
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
During this study, no patient receiving TDF and FTC was admitted to intensive care or died.
The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.
Consider these steps for pharmacists to further evolve their role as the pandemic continues to put pressure on the health care system.
National Comprehensive Cancer Network Issues Guidance on COVID-19 Vaccination for Patients With Cancer
NCCN states that all patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the COVID-19 vaccines granted emergency use authorization.
The FDA has approved cabenuva, which consists of rilpivirine and cabotegravir, for treating HIV-1 infection in adults. This therapy is the first once-monthly, long-acting injectable to be approved for the treatment of HIV.
FDA Approves Nivolumab in Combination With Cabozantinib As First-Line Treatment for Advanced Renal Cell Carinoma
The approval is for a 240 mg injection of nivolumab every 2 weeks or 480 mg every 4 weeks in combination with 40 mg once daily of cabozantinib.
Student Café: Impact of COVID-19 on Pharmacy Education
Pharmacy students discuss how has the coronavirus disease 2019 (COVID-19) has impacted their education and preparation for future careers.